“…The most serious clinical problem is that in the course of treatment PC becomes refractory to hormone manipulation, known as metastatic castration-resistant prostate cancer (mCRPC) [2,4]. There are many options for the treatment of mCRPC including docetaxel, abiraterone acetate, enzalutamide, cabazitaxel, radium-223, Sipuleucel-T (the only cancer vaccine approved to treat advanced PC so far) [3,4,5,6,7,8], and radioligand therapy (RLT) directed against prostate-specific membrane antigen PSMA, which could be successfully used as a third line therapy of mCRPC [9,10,11].…”